Amphastar Pharmaceuticals Inc
Research Amphastar Pharmaceuticals Inc (AMPH) on Bullrun: market cap USD 934.86M, P/E 12.9. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAMPH
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 934.86M
- P/E12.9
- Financial periodQ2 2026
- RevenueUSD 183.90M
- Net incomeUSD 30.35M
- Free cash flowUSD 42.73M
- Gross margin50.8%
Valuation Snapshot
latest market cap is USD 934.86M; P/E is 12.9.
Peer valuation comparison
Latest P/E is 12.88x versus a Healthcare sector median of 24.46x (47.3% below).
Latest P/E is 12.88x versus a United States median of 24.87x (48.2% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 719.89M | USD 98.09M | USD 121.23M | 49.5% | 2.03 | USD 170.18M | USD 619.71M | USD 788.81M |
| FY2024 | USD 731.97M | USD 159.52M | USD 172.35M | 51.1% | 3.06 | USD 151.61M | USD 613.53M | USD 732.30M |
| FY2023 | USD 644.40M | USD 137.55M | USD 145.34M | 54.5% | 2.6 | USD 144.30M | USD 603.17M | USD 639.42M |
| FY2022 | USD 498.99M | USD 91.39M | USD 65.15M | 49.9% | 1.74 | USD 156.10M | USD 76.64M | USD 528.66M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 934.86M | 12.9 | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.22B | 13.2 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.77B | 12.1 | n/a | n/a |
| 2023 | 2023-12-29 | USD 2.96B | 24.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.35B | 18.8 | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.11B | 18.8 | n/a | n/a |
About Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Amphastar Pharmaceuticals Inc's market cap?
Amphastar Pharmaceuticals Inc's market capitalization is USD 934.86M.
What is Amphastar Pharmaceuticals Inc's P/E ratio?
Amphastar Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 12.9.
What does Amphastar Pharmaceuticals Inc do?
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France.